Articles by William Looney - Pharmaceutical Executive


Articles by William Looney

William Looney

Ireland's Celtic Tiger: Back on the Hunt
September 1, 2014

Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.

13 Years Right
September 1, 2014

Pharm Exec's latest Industry Audit sticks to the series' longtime standard of emphasizing transparent indicators of shareholder value.

A Window on the Industry: The Emerging Pharma Leaders 2014
August 1, 2014

Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success, writes William Looney.

Brown University's Masters in Healthcare Leadership: A Mission to Transform
August 1, 2014

Mid-career students on Brown University's new program are challenged to remove the organizational silos that slow innovations in the delivery and financing of healthcare.

The Peace Dividend
July 10, 2014

A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.

Pharm Exec's 2014 Dealmakers Outlook
July 10, 2014

As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead for M&A, licensing, and partnership activity.

Pharma 50 Trends: Past, Present, and Future
June 9, 2014

Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.

What's Real in Deals
May 1, 2014

Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.

2014 Brand of the Year
May 1, 2014

Pharm Exec's Brand of the Year recipients for 2014 are multiple sclerosis treatment Copaxone and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs.


Click here